Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Hodgkin Disease

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Hodgkin Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Vinorelbine

Ifosfamide

Lenograstim

Isophosphamide mustard

Antimetabolites

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Alkylating

Alkylating Agents

Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle

Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle

gemcitabine, vinorelbine, ifosfamide, filgastrim

gemcitabine, vinorelbine, filgastrim

Andrew Spencer, Assoc. Prof

This is a Phase II trial evaluating the efficacy (overall response rate) of a risk-adjusted outpatient based approach to lymphoma salvage therapy with vinorelbine, gemcitabine and pegfilgrastim and/or gemcitabine, ifosfamide, vinorelbine and pegfilgrastim.

Lymphoma has been increasing in incidence annually for the past several decades and the majority of patients relapse after first line therapy. A variety of 'salvage chemotherapy' treatments are available that are usually inpatient-based treatments associated with significant haematological toxicity. Furthermore, all patients are treated in the same manner despite the fact that some patients will do well irrespective of the type of salvage therapy whereas others will do badly no matter what is done. During 2001-2002 we undertook a pilot study in 40 such patients using an outpatient-based salvage therapy with 2 newer chemotherapy drugs, vinorelbine and gemcitabine. Over 75% of all treatments were successfully delivered on an outpatient basis with response rates similar to historical controls. We now propose to expand on these initial findings by modifying the outpatient approach for those patients with less favourable prognostic features, that is, patients will be stratified to differing therapies but with the majority still receiving the proven vinorelbine-gemcitabine combination.

Efficacy Study of Outpatient Therapy for Lymphoma

A Multicentre Phase II Study of Risk-adjusted Outpatient-based Salvage Therapy for Patients With Relapsed and Refractory Lymphoma

Bayside Health

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy Study of Outpatient Therapy for Lymphoma	NCT00163761	Non-Hodgkin's L... Hodgkin's Disea...	gemcitabine, vi... gemcitabine, vi...	18 Years -	Bayside Health
Efficacy Study of Outpatient Therapy for Lymphoma	NCT00163761	Non-Hodgkin's L... Hodgkin's Disea...	gemcitabine, vi... gemcitabine, vi...	18 Years -	Bayside Health

Spots Global Cancer Trial Database for gemcitabine, vinorelbine, filgastrim